Clik here to view.
Novartis to Cut 4,000 Jobs as Part of Restructuring Move
Source: http://www.novartis.com/index.shtml Novartis AG (NYSE:NVS) is continuing its cost cutting, this time by cutting or transferring up to 4,000 jobs, or approximately 6 percent of its workforce,...
View ArticleClik here to view.
Pfizer Wins Exclusivity on Lyrica Until 2018
Pfizer Inc. (NYSE:PFE) has won a court ruling that effectively blocks all generic competition of the company’s top-selling product, Lyrica, a pain medicine. Generic competitors won’t be allowed to...
View ArticleClik here to view.
Merck Aims to Be First to the Finish Line With Generic of Lantus
Source: http://www.flickr.com/photos/andresrueda/ U.S. pharmaceutical company Merck & Co. Inc. (NYSE:MRK) announced Monday that it’s partnering with Samsung Bioepis to create a generic version of...
View ArticleClik here to view.
Pfizer Unit Sued by Regulator for ‘Deterring Competition’
The Australian Competition and Consumer Commission said Thursday that it filed a lawsuit in the country’s federal court against Pfizer Inc.(NYSE:PFE), claiming that the company’s Australian unit made...
View ArticleClik here to view.
Teva’s New Version of Copaxone Could Be a Tough Bet for Insurers
In a moment of desperation, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is attempting to persuade multiple sclerosis patients who currently use its drug, Copaxone, to switch to a newer version of...
View ArticleClik here to view.
Supreme Court Studies Generic Drug Question: How Will Patients Fare?
Source: http://www.flickr.com/photos/waywuwei/ Perhaps not as attention-grabbing as the health care industry’s struggle to adapt to the changes brought by the Affordable Care Act, its efforts to deal...
View ArticleClik here to view.
Generic Drugmakers Fight Teva’s Bid to Stall Competition
Generic drugmakers asked the U.S. Supreme Court to allow them to introduce generic versions of Teva Pharmaceutical Industries Ltd.’s (NYSE:TEVA) Copaxone multiple-sclerosis drug onto the market next...
View ArticleClik here to view.
In Last-Ditch Effort to Salvage Blockbuster Drug, Teva Sues the FDA
Source: Thinkstock In a last-ditch attempt to prevent generic versions of its multiple sclerosis drug, Copaxone, Teva Pharmaceutical Industries (NYSE:TEVA) has decided to sue U.S. regulators, claiming...
View ArticleClik here to view.
Which Do You Want First? Teva Pharmaceutical’s Good and Bad News
Source: Thinkstock We’ll start with the bad news: In a decision unlikely to surprise anyone, Teva Pharmaceutical Industries (NYSE:TEVA) has been shot down in its attempt to sue the U.S. Food and Drug...
View ArticleClik here to view.
3 Reasons to Be Bullish on Teva
Teva Pharmaceutical Inudstries Ltd. (NYSE:TEVA) has had a bit of a rough year so far: the first quarter of 2014 seems to have been primarily taken up by Teva’s attempts at winning an ongoing battle to...
View Article
